Prevalence and Significance of Potential Pharmacokinetic Drug-Drug Interactions Among Patients with Lung Cancer: Implications for Clinical Trials.

Sawsan RashdanHui YangTri LeChristopher SelbyDavid E GerberCarlos A Alvarez

Published in: Clinical drug investigation (2021)

Medications with potential DDIs are prescribed to the majority of patients with lung cancer; however, only about 5% of patients are prescribed medications with major DDIs that might be prohibited in certain clinical trials.

Keyphrases

clinical trial
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
risk factors
prognostic factors
emergency department
phase ii
randomized controlled trial
human health
open label
double blind